This open-label, prospective, multi-center, non-interventional, observational, parallel cohort study intended to provide real life data on the treatment duration, effectiveness and safety of tedizolid and linezolid when treating ABSSSI hospitalized patients in a real practice setting.
The primary objective of this study was to assess the treatment duration in the real life in 2 cohorts consisting of patients treated by 200 mg once daily IV/PO tedizolid or treated by 600 mg twice daily IV/PO (intravenous/per oral) linezolid.
Study Type
OBSERVATIONAL
Enrollment
108
Antibiotic
Antibiotic
Unnamed facility
Multiple Locations, Mexico
Unnamed facility
Multiple Locations, Russia
Unnamed facility
Multiple Locations, Singapore
Number of treatment days
Duration of treatment is defined as the time interval from date of first administration of tedizolid or linezolid to the date of permanent discontinuation of tedizolid or linezolid, respectively. The treatment is according to the recommendations written in the local product information.
Time frame: Up to 1 month
Number of participants with adverse events or safety-relevant changes in laboratory parameters
Time frame: Up to 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.